Trial · NCT02983045
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Part 1 Dose Escalation Cohort 1: NKTR-214 (0.006 mg/kg) q3w + Nivolumab (240 mg) q2w | 4 | |
| Overall Study | STARTED | Part 1 Dose Escalation Cohort 2: NKTR-214 (0.006 mg/kg) q2w + Nivolumab (240 mg) q2w | 3 | |
| Overall Study | STARTED | Part 1 Dose Escalation Cohort 3: NKTR-214 (0.003 mg/kg) q2w + Nivolumab (240 mg) q2w | 3 | |
| Overall Study | STARTED | Part 1 Dose Escalation Cohort 4: NKTR-214 (0.006 mg/kg) q3w + Nivolumab (360 mg) q3w | 25 | |
| Overall Study | STARTED | Part 1 Dose Escalation Cohort 5: NKTR-214 (0.009 mg/kg) q3w + Nivolumab (360 mg) q3w | 3 | |
| Overall Study | STARTED | Part 2 Dose Expansion: NKTR-214 (0.006 mg/kg) q3w + Nivolumab (360 mg) q3w | 476 | |
| Overall Study | STARTED | Part 3 Schedule Finding (Schedule 1): NKTR-214 + Nivolumab + Ipilimumab | 10 | |
| Overall Study | STARTED | Part 3 Schedule Finding (Schedule 2): NKTR-214 + Nivolumab + Ipilimumab | 8 | |
| Overall Study | STARTED | Part 3 Schedule Finding (Schedule 3): NKTR-214 + Nivolumab + Ipilimumab | 6 | |
| Overall Study | STARTED | Part 4 Dose Expansion of NKTR-214 + Nivolumab + Ipilimumab | 19 | |
| Overall Study | COMPLETED | Part 1 Dose Escalation Cohort 1: NKTR-214 (0.006 mg/kg) q3w + Nivolumab (240 mg) q2w | 4 | |
| Overall Study | COMPLETED | Part 1 Dose Escalation Cohort 2: NKTR-214 (0.006 mg/kg) q2w + Nivolumab (240 mg) q2w | 2 | |
| Overall Study | COMPLETED | Part 1 Dose Escalation Cohort 3: NKTR-214 (0.003 mg/kg) q2w + Nivolumab (240 mg) q2w | 3 | |
| Overall Study | COMPLETED | Part 1 Dose Escalation Cohort 4: NKTR-214 (0.006 mg/kg) q3w + Nivolumab (360 mg) q3w | 20 | |
| Overall Study | COMPLETED | Part 1 Dose Escalation Cohort 5: NKTR-214 (0.009 mg/kg) q3w + Nivolumab (360 mg) q3w | 3 | |
| Overall Study | COMPLETED | Part 2 Dose Expansion: NKTR-214 (0.006 mg/kg) q3w + Nivolumab (360 mg) q3w | 394 | |
| Overall Study | COMPLETED | Part 3 Schedule Finding (Schedule 1): NKTR-214 + Nivolumab + Ipilimumab | 10 | |
| Overall Study | COMPLETED | Part 3 Schedule Finding (Schedule 2): NKTR-214 + Nivolumab + Ipilimumab | 8 | |
| Overall Study | COMPLETED | Part 3 Schedule Finding (Schedule 3): NKTR-214 + Nivolumab + Ipilimumab | 6 | |
| Overall Study | COMPLETED | Part 4 Dose Expansion of NKTR-214 + Nivolumab + Ipilimumab | 17 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02983045/flow